Published by Global Banking & Finance Review
Posted on November 16, 2026
· Last updated: November 16, 2026
Sofinnova Closes €725 Million Fund for European Biotech Growth
Sofinnova's Latest Fund and Its Impact on European Biotech
By Bhanvi Satija
Fundraising Success and Purpose
LONDON, Nov 16 (Reuters) - Life sciences investment firm Sofinnova Partners said on Monday it has closed a second crossover fund at €725 million ($799 million), above its original target, to back European biotechs that are seeking to compete globally.
A crossover fund typically invests in private companies approaching commercialisation or public listings, bridging the gap between venture capital and public-market investing.
European Biotech Landscape
The raise comes at a time when drugmakers are pushing European governments to increase spending on medicines, faster trials and other policies that would prevent the region from losing ground to the US and China.
At the same time, cash-strapped governments in Europe are under pressure to rethink how they pay for innovative medicines.
Europe has outstanding science and companies, said Kinam Hong, a partner at Sofinnova, told Reuters in an interview.
"It doesn’t have an innovation gap, but it really has a financing growth capital problem," he said.
Sofinnova’s Investment Strategy
Hong said the fund, called Crossover II, is the biggest ever for the firm and will focus on European biotechs and medtech companies looking to commercialise their medicines or devices, with some selective investments in the US and elsewhere.
Through the fund, Sofinnova expects to back about 15 companies and has already invested in rare-disease biotech Hemab Therapeutics, multiple myeloma drug developer CellCentric and Neurent Medical, a chronic rhinitis device maker.
Hong said the firm plans to be an active investor, helping companies with leadership, trials and listings. He added that the aim is to build companies for "successful longevity" even without mergers and acquisitions.
Track Record and Assets Under Management
The firm's first Crossover fund had backed Amolyt Pharma, a developer of treatments for rare hormone disorders that was acquired by AstraZeneca, as well as the French biotech Abivax, which is developing an ulcerative colitis drug.
Sofinnova manages more than €4 billion ($4.4 billion) in assets across healthcare and sustainability.
($1 = 0.9073 euros)
(Reporting by Bhanvi Satija in London, Editing by Louise Heavens)
Key Takeaways
- Crossover II fund, the firm’s biggest yet, raised €725 million (≈$815 million), above target, to back late-stage European biotechs and medtech firms, with selective U.S. investments (fiercebiotech.com)
- The fund will support approximately 15 clinical‑stage companies, already backing Hemab Therapeutics, CellCentric and Neurent Medical (ansa.it)
- Sofinnova now manages over €4 billion in assets across its healthcare and sustainability strategies, and sees this fund as bridging Europe’s scale‑up financing gap (sofinnovapartners.com)
References
- Sofinnova books $815M fund toward up-and-coming ‘global leaders’
- Sofinnova Partners chiude a 725 milioni di euro la raccolta del fondo Crossover II - Business Wire - Ansa.it
- Sofinnova Partners raises €1.2 billion for life sciences — Sofinnova Partners
Frequently Asked Questions
Tags
Related Articles
ECB VP says AI, debt have become prominent stability risks
Germany's Uniper expects core profit of up to €1.5 billion in 2027
British insurer L&G's third-quarter outflows slow, retail momentum holds strong
Carmila plans takeover of Italy's IGD to form group with €9 billion property portfolio
Global banks set to enter 2027 on strong footing, Moody's report says
UK's Unite union says Apache offshore workers escalate strike action
More from Finance
Explore more articles in the Finance category



